Company news

Cogstate Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Retail Entitlement Offer

October 27, 2019

Successful completion of Institutional Entitlement Offer

October 21, 2019

Underwritten Accelerated Non-Renounceable Entitlement Offer

October 20, 2019

Business Update and Appendix 4C

October 15, 2019

FY19 Full Year Results

August 27, 2019

Appendix 4E and Preliminary Final Report

August 27, 2019

Licence of Cogstate Technology and Share Placement

August 27, 2019

Issue of Placement Shares

July 8, 2019

FY19 Half Year Results and Earnings Guidance

February 26, 2019

Change of Director’s Interest Notice

October 29, 2018

AGM Presentation

October 23, 2018

Full Year Financial Results Summary

August 12, 2018

AD trial discontinued - limited CGS impact

June 12, 2018

Cogstate announces European approval for Cognigram

June 4, 2018

Business Update & Appendix 4C

April 12, 2018

Cogstate Establishes Rare Disease and Pediatric Expertise

April 5, 2018

S&P DJ Indices Announces March Quarterly Rebalance

March 8, 2018

Appendix 4D & Half Year Financial Report

February 20, 2018

Global Alzheimer Platform Foundation Selects Cogstate

January 24, 2018

Interim Business Update

December 5, 2017

Cogstate cleared by FDA to start marketing Cognigram in U.S.

July 26, 2017

FY17 Earnings Update

July 10, 2017

Cogstate selected as preferred provider for Lilly

May 17, 2017

Appendix 4D and Half-Year Financial Report

February 22, 2017

Cogstate enters into agreement with Clinical Ink

October 25, 2016

2016 Financial Year Results

August 17, 2016

Chairmans Address to Shareholders

March 30, 2016

JV Agreement Signed

March 30, 2016

CogState 2010 AGM Address

March 30, 2016

NRL mandates use of CogState for concussion management

March 30, 2016

Growth in sales contracts delivers strong Q1 results

March 30, 2016

CogState Tests Used in Successful Ph 2 Schizophrenia Study

March 30, 2016

CogState announces partnership in area of cognitive training

March 30, 2016

CogState Again Used in Successful Schizophrenia Study

March 30, 2016

Business Update - Unaudited Full Year Profit Results

March 30, 2016

CogState signs sales contract for phase 3 study

March 30, 2016

CogState signs sales contract for phase 2 study

March 30, 2016

CogState signs sales contract for large phase 2 study

March 30, 2016

CogState Signs Contract For Phase 2 Schizophrenia Study

March 30, 2016

CogState partners with Merck Canada

March 30, 2016

Merck releases new data on effectiveness of Cognigram

March 30, 2016

Growing recognition of Cogstate test as a cognitive tool

March 30, 2016

CogState launches Cognigram test in Canada

March 30, 2016

Fully Underwritten Non-Renounceable Rights Issue / Placement

March 30, 2016

Business Update and First Half Financial Guidance

March 30, 2016

30 Sep 2013 Business Update and Appendix 4C

March 30, 2016

Precision Recruitment chosen for phase III Alzheimers study

March 30, 2016

Contracts signed since 1 July 2014 hit $9 million

March 30, 2016

Cogstate Test to be used in large paediatric clinical trial

March 30, 2016

Cogstate signs first client to Precision Recruitment

March 30, 2016

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 69 decks. Every deck is listed under its year.